SRx Health Solutions, Inc. — fact timeline

SRx Health Solutions, Inc. issued 22,237,666 Warrants to purchase shares of Common Stock of warrant to accredited investors named therein for aggregate proceeds of approximately $4.528 million, paid in cash.

“On March 16, 2026 at the initial closing, pursuant to the Securities Purchase Agreement, the Company issued and sold, and certain investors purchased, in a private placement (the “Private Placement”): 5,660 shares of the Series B Preferred Stock and 22,237,666 Warrants to purchase shares of Common Stock for aggregate proceeds of approximately $4.528 million, paid in cash.”

SRx Health Solutions, Inc. issued 5,660 shares of the Series B Preferred Stock of preferred stock to accredited investors named therein for aggregate proceeds of approximately $4.528 million, paid in cash.

“On March 16, 2026 at the initial closing, pursuant to the Securities Purchase Agreement, the Company issued and sold, and certain investors purchased, in a private placement (the “Private Placement”): 5,660 shares of the Series B Preferred Stock and 22,237,666 Warrants to purchase shares of Common Stock for aggregate proceeds of approximately $4.528 million, paid in cash.”

SRx Health Solutions, Inc. entered into Securities Purchase Agreement with certain accredited investors named therein valued at up to $8.0 million (effective 2026-03-16).

“On March 16, 2026, SRx Health Solutions, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accredited investors named therein. Pursuant to the Securities Purchase Agreement, up to 10,000 shares of the Company’s Series B convertible preferred stock, par value $0.001 per share (the “Series B Preferred Stock”) and accompanying warrants (“Warrants”) to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) may be purchased for an aggregate purchase price of up to $8.0 million in one or more closings (each a “Closing”).”

SRx Health Solutions, Inc. entered into Waiver with certain Existing Investors.

“certain Existing Investors have each entered into a limited waiver and consent agreement with the Company (each, a “Waiver”)”

SRx Health Solutions, Inc. entered into New Securities Purchase Agreement with certain accredited investors.

“The Company desires to enter into a securities purchase agreement (the “New Securities Purchase Agreement”) with certain accredited investors (the “New Buyers”)”

SRx Health Solutions, Inc. received a nyse_american noncompliance notice notice regarding other (rules 301, 713).

“February 18, 2026, SRx Health Solutions, Inc. (the “Company”) received a public warning letter (the “Letter”) from the NYSE Regulation Staff of the New York Stock Exchange (the “Exchange”) notifying the Company that it failed to comply with Sections 301 and 713 of the NYSE American LLC Company Guide (the “Company Guide”). The Letter relates to the issuance of approximately 7.5 million shares (the “Subject Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), between December 31, 2025 and January 23, 2026, upon conversion of certain shares of the Company’s Ser”

SRx Health Solutions, Inc. received a nyse_american extension granted notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii)).

“January 6, 2026, SRx Health Solutions, Inc. (the “Company”), received a notice from the NYSE American (“NYSE”), that NYSE has accepted the Company’s plan to regain compliance with Sections 1003(a)(i) and (ii) of the NYSE American Company Guide. As previously disclosed, NYSE notified the Company on October 14, 2025, that the Company had fallen below the NYSE’s continued listing standard requiring a listed company to have stockholders’ equity of $4 million or more if the listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years.”

SRx Health Solutions, Inc. entered into Share Exchange and Asset Transfer Agreement with EMJ Crypto Technologies Inc., CCC Crypto Corp., and the transferors named therein valued at approximately $55 million (effective 2025-12-16).

“On December 16, 2025, SRx Health Solutions, Inc. (the “Company”) entered into a Share Exchange and Asset Transfer Agreement (the “Transfer Agreement”), as unanimously approved by the Board, by and among the Company, EMJ Crypto Technologies Inc., a corporation organized under the laws of Ontario, Canada (“EMJC”), CCC Crypto Corp., a Delaware corporation (“DelawareCo”), and the transferors named therein (the “Transferors”).”

SRx Health Solutions, Inc.: Increased authorized common shares from 200,000,000 to 5,000,000,000 (effective 2025-11-19).

“The amendment increases the number of authorized shares of the Company’s capital stock. Specifically, the Certificate of Amendment provides that the total number of shares of shares of common stock, par value $0.001 per share, that the Company is authorized to issue is increased from 200,000,000 shares to 5,000,000,000 shares.”

SRx Health Solutions, Inc. issued 54,527,811 Warrants to purchase shares of Common Stock of warrant to certain accredited investors for aggregate proceeds of approximately $15.23 million.

“On October 31, 2025, pursuant to the Securities Purchase Agreement, the Company issued and sold, and certain investors purchased, in a private placement (the “Private Placement”): 19,035 shares of the Series A Preferred Stock and 54,527,811 Warrants to purchase shares of Common Stock for aggregate proceeds of approximately $15.23 million”

SRx Health Solutions, Inc. issued 19,035 shares of the Series A Preferred Stock of preferred stock to certain accredited investors for aggregate proceeds of approximately $15.23 million.

“On October 31, 2025, pursuant to the Securities Purchase Agreement, the Company issued and sold, and certain investors purchased, in a private placement (the “Private Placement”): 19,035 shares of the Series A Preferred Stock and 54,527,811 Warrants to purchase shares of Common Stock for aggregate proceeds of approximately $15.23 million”

SRx Health Solutions, Inc. incurred convertible notes of $20 million with Investor.

“the Company issued to Investor a convertible promissory note in the aggregate principal amount of $20 million.”

SRx Health Solutions, Inc. amended credit facility of from $50 million to $1 billion with Investor.

“greement (the “Securities Purchase Agreement”) with certain accredited investors named therein. Pursuant to the Securities Purchase Agreement, up to 38,070 shares of the Company’s Series A convertible preferred stock, par value”

SRx Health Solutions, Inc. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(ii)).

“October 14, 2025, SRx Health Solutions, Inc, a Delaware corporation. (the “Company”) received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standard set forth in Section 1003(a)(ii) of the NYSE American Company Guide (“Section 1003(a)(ii)”). Section 1003(a)(ii) requires a listed company to have stockholders’ equity of $4 million or more if the listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years.. T”

SRx Health Solutions, Inc. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(ii), 1009).

“October 14, 2025, SRx Health Solutions, Inc, a Delaware corporation. (the “Company”) received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standard set forth in Section 1003(a)(ii) of the NYSE American Company Guide (“Section 1003(a)(ii)”). Section 1003(a)(ii) requires a listed company to have stockholders’ equity of $4 million or more if the listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years.. T”

SRx Health Solutions, Inc. engaged Davidson and Company LLP as its auditor.

“the Board of Directors of the Company, upon the recommendation of the Audit Committee, approved the dismissal of CBIZ, and approved and ratified the engagement of Davidson and Company LLP (“Davidson”) as the Company’s independent registered public accounting firm”

SRx Health Solutions, Inc. dismissed CBIZ CPAs P.C. as its auditor.

“On September 15, 2025, SRx Health Solutions, Inc. (formerly known as Better Choice Company, Inc.) (the “Company”), notified CBIZ CPAs P.C. (“CBIZ”) that it was being dismissed as the Company’s independent registered public accounting firm.”

SRx Health Solutions, Inc. completed an acquisition involving SRx Health Solutions (Canada), Inc. (closed 2025-04-24).

“On April 24, 2025 (the “Closing Date”), SRx Health Solutions, Inc., a Delaware corporation (f/k/a Better Choice Company, Inc.) (the “Company” or the “Registrant” or “we”, “us” or “our”) announced that it closed the business combination (the “Business Combination”) by and among the Company, 1000994476 Ontario Inc., an Ontario corporation (“AcquireCo”), 1000994085 Ontario Inc., an Ontario Corporation (“CallCo”) and SRx Health Solutions (Canada), Inc., an Ontario corporation (f/k/a SRx Health Solutions, Inc.) (“SRx Canada”), whereby the Company acquired SRx Canada pursuant to the terms of an Arrangement Agreement and Plan of Arrangement entered into on September 2, 2024, by and among the Company, AcquireCo, CallCo and SRx Canada (the “Arrangement Agreement”).”

Lionel Conacher was appointed as Chairman of the Board at SRx Health Solutions, Inc..

“Kent Cunningham, 54, has been appointed as President of the Company; Adesh Vora, 49, has been appointed as Chief Executive Officer of the Company; and Lionel Conacher, 62, has been appointed as Chairman of the Board, in each case effective June 11, 2025.”

Adesh Vora was appointed as Chief Executive Officer at SRx Health Solutions, Inc..

“Kent Cunningham, 54, has been appointed as President of the Company; Adesh Vora, 49, has been appointed as Chief Executive Officer of the Company; and Lionel Conacher, 62, has been appointed as Chairman of the Board, in each case effective June 11, 2025.”

Kent Cunningham was appointed as President at SRx Health Solutions, Inc..

“Kent Cunningham, 54, has been appointed as President of the Company; Adesh Vora, 49, has been appointed as Chief Executive Officer of the Company; and Lionel Conacher, 62, has been appointed as Chairman of the Board, in each case effective June 11, 2025.”

Davender Sohi resigned as President at SRx Health Solutions, Inc..

“On June 10, 2025, SRx Health Solutions, Inc. (the “ Company ”) accepted the voluntary resignation of Davender Sohi as the President of the Company, effective immediately.”

SRx Health Solutions, Inc.: Amended certificate of incorporation to change company name from Better Choice Company Inc. to SRx Health Solutions, Inc (effective 2025-04-24).

“On April 24, 2025, concurrent with the Merger, we amended our certificate of incorporation to change the name of the Company from "Better Choice Company Inc." to "SRx Health Solutions, Inc."”

SRx Health Solutions, Inc. underwent a change of control involving 1000994476 Ontario Inc. for 8,898,069 shares of the Company’s common stock and 19,701,935 Exchangeable Shares (closed 2025-04-24).

“continue the existing business operations of SRx Health as a wholly-owned subsidiary. On the Closing Date, Predecessor issued to certain holders of the common stock of SRx Health 8,898,069 shares of the Company’s common stock, par value $0.001 per share (the “ Company Common Stock ”), and AcquireCo issued to certain holders of the common stock of SRx Health”

SRx Health Solutions, Inc. engaged CBIZ CPAs P.C. as its auditor.

“On April 23, 2025, Marcum resigned as the Company’s independent registered public accounting firm, and CBIZ CPAs was engaged to serve as the independent registered public accounting firm of the Company for the year ending December 31, 2025, effective immediately.”

Marcum LLP resigned as auditor of SRx Health Solutions, Inc..

“On April 23, 2025, Marcum resigned as the Company’s independent registered public accounting firm, and CBIZ CPAs was engaged to serve as the independent registered public accounting firm of the Company for the year ending December 31, 2025, effective immediately.”

SRx Health Solutions, Inc. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(ii), 1003(a)(iii)).

“April 24, 2024, notifying the Company that it is no longer in compliance with NYSE American continued listing standards. Specifically, the letter states that the Company is not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”). Section 1003(a)(ii) requires a listed company to have stockholders’ equity of $4 million or more if the listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. Section 1003(a)(iii) requires a”

SRx Health Solutions, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.

“Better Choice Company Inc., a Delaware corporation (“the Company”), announced its financial results for the fourth quarter and year ended December 31, 2023.”

Kent Cunningham was appointed as Director at SRx Health Solutions, Inc..

“On April 3, 2024, the Board appointed Kent Cunningham, the Company’s Chief Executive Officer, as a director of the Company, effective immediately,”

Arlene Dickinson resigned as Director at SRx Health Solutions, Inc..

“Arlene Dickinson resigned from the Board of Directors (the “Board”) of Better Choice Company Inc., a Delaware corporation (the “Company”) and all committees of the Board effective as of April 1, 2024.”

SRx Health Solutions, Inc.: Certificate of Amendment to Certificate of Incorporation to effectuate a 1-for-44 reverse stock split (effective 2024-03-20).

“On March 20, 2024, Better Choice Company Inc. (the “ Company ”) filed a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware (the “ Certificate of Amendment ”) to effectuate a reverse stock split (the “ Reverse Stock Split ”) of its issued and outstanding shares of common stock on a 1-for-44 basis.”

SRx Health Solutions, Inc. shareholders approved Advisory (non-binding) approval of compensation of named executive officers at the 2023-11-15 meeting.

“The compensation of the Company’s named executive officers was approved, on an advisory (non-binding) basis, with votes as follows: FOR AGAINST ABSTAIN BROKER NON-VOTE 13,838,601 903,204 8,798 4,398,549”

SRx Health Solutions, Inc. shareholders approved Reaffirmation of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-11-15 meeting.

“The reaffirmation of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified, with votes as follows: FOR AGAINST ABSTAIN 18,417,460 119,791 611,901”

SRx Health Solutions, Inc. shareholders approved Approval of issuance of common stock upon exercise of the Alphia Second Tranche Warrant at the 2023-11-15 meeting.

“The vote to approve the issuance of common stock upon exercise of the Alphia Second Tranche Warrant, was as follows: FOR AGAINST ABSTAIN BROKER NON-VOTE 13,915,282 821,350 13,971 4,398,549”

SRx Health Solutions, Inc. shareholders approved Election of directors at the 2023-11-15 meeting.

“Each of the following persons was duly elected to serve as a director of the Company’s board of directors for a term expiring at the 2024 annual meeting of stockholders and until his or her successor shall have been elected and qualified or until earlier resignation, removal from office or death, with votes as follows:”

SRx Health Solutions, Inc. reported nine months ended September 30, 2023 results: revenue $32.9 million, net income $(8.1) million, EPS ($0.26).

“loss improved 46% YOY to $(8.1) million ● EPS improved 48% YOY to ($0.26) ● Adjusted EBITDA improved 47% YOY to $(3.8) million 1 ● Adjusted”

SRx Health Solutions, Inc. reported third quarter ended September 30, 2023 results: revenue $13.1 million, net income $(1.6) million, EPS ($0.05).

“Revenue increased 24% from second quarter 2023, and 11% year-over-year (“YOY”) to $13.1 million”

SRx Health Solutions, Inc. received a nyse_american deficiency notice notice regarding minimum bid price (rules 1003(f)(v)).

“September 21, 2023, Better Choice Company, Inc. (the “Company”) received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standard set forth in Section 1003(f)(v) of the NYSE American Company Guide (“Section 1003(f)(v)”) because shares of the Company's common stock have been selling for a substantial period of time at a low price per share. The Notice has no immediate effect on the listing or trading of the Company’s common stock and the common stock will continue to trade”

Donald Young resigned as Chief Sales Officer at SRx Health Solutions, Inc..

“Donald Young, age 59, has resigned from his role as Chief Sales Officer of the Company, effective September 8, 2023.”

SRx Health Solutions, Inc. reported second quarter ended June 30, 2023 results: revenue $10.5 million, net income $(3.0) million, EPS $(0.10).

“Net revenue increased 14% from first quarter 2023 to $10.5 million”

Carolina Martinez was appointed as Chief Financial Officer at SRx Health Solutions, Inc..

“Carolina Martinez, age 33, was appointed as Chief Financial Officer of the Company, effective August 2, 2023.”

SRx Health Solutions, Inc. incurred credit facility of up to $4,750,000 with Wintrust Receivables Finance, a division of Wintrust Bank N.A. at a minimum rate of 5.5% maturing an initial term of two years.

“Wintrust Facility On June 21, 2023, Halo entered into an account purchase agreement (the “AP Agreement”) with Wintrust Receivables Finance, a division of Wintrust Bank N.A. (“Wintrust”) pursuant to which Wintrust will purchase, at its discretion, up to eligible customer invoices and advance up to 75% of the face amount of all purchased invoices up to $4,750,000 (the “Wintrust Facility”).”

SRx Health Solutions, Inc. incurred term loan of $5,000,000 with Alphia Inc. at 10% per annum, compounded quarterly maturing June 21, 2026.

“Pursuant to the Term Loan Agreement, Alphia made a term loan to the Company in the original principal amount of $5,000,000 (the “Term Loan”).”

SRx Health Solutions, Inc. entered into AP Agreement with Wintrust Receivables Finance, a division of Wintrust Bank N.A. valued at up to $4,750,000 (effective 2023-06-21).

“entered into an account purchase agreement (the “AP Agreement”) with Wintrust Receivables Finance, a division of Wintrust Bank N.A. (“Wintrust”)”

SRx Health Solutions, Inc. entered into Term Loan Agreement with Alphia Inc. valued at $5,000,000 (effective 2023-06-21).

“(NYSE: BTTR) (the “Company”), a pet health and wellness company, entered into a term loan credit agreement (the “Term Loan Agreement”) with Alphia Inc. (“Alphia”), a leading custom manufacturer of super-premium pet food in the U.S.”

Kent Cunningham was appointed as Chief Executive Officer at SRx Health Solutions, Inc..

“On May 11, 2023, the Company announced that Kent Cunningham, age 52, was appointed as Chief Executive Officer of the Company, effective May 22, 2023.”

Lionel F. Conacher resigned as Interim Chief Executive Officer at SRx Health Solutions, Inc..

“Lionel F. Conacher, age 60, will resign from his role as Interim Chief Executive Officer of the Company, effective May 22, 2023.”

SRx Health Solutions, Inc. reported financial results for first quarter ended March 31, 2023.

“On May 12, 2023, Better Choice Company Inc., a Delaware corporation (the “ Company ”), announced its financial results for the first quarter ended March 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1.”

SRx Health Solutions, Inc. reported the year ended December 31, 2022 results: revenue $54.7 million, net income $(39.3) million.

“and Current Reports on Form 8-K. --- EX-99.1 (EX-99.1) --- Better Choice Company Reports Fourth Quarter and Full Year 2022 Financial Results Year-to-Date Net Sales Totaled $54.7 million, an Increase of 19% Year-over-Year Year-to-Date Gross Margin of 28%, or 31% Excluding the Impact of Inventory Rationalization NEW YORK, NY, March 28, 2023 -- Better Choice”

SRx Health Solutions, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $9.3 million, net income $24.4 million.

“results for the fourth quarter and year ended December 31, 2022. Lionel F. Conacher, Interim CEO of Better Choice, stated, “During the fourth quarter, net sales were sales were $9.3 million resulting in full year 2022 net sales of $54.7 million, a 19% increase versus the prior year. Our International channel delivered year-over-year net sales growth of 48% and Brick”